Advice
Following an abbreviated submission
methotrexate injection 50mg/ml (Metoject) is accepted for use in NHS Scotland for the treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis in adult patients.
For patients in whom parenteral methotrexate is appropriate, this is the first licensed parenteral formulation for this indication
Download detailed advice44KB (PDF)
Medicine details
- Medicine name:
- methotrexate (Metoject 50mg/ml)
- SMC ID:
- 573/09
- Indication:
- Severe recalcitrant disabling psoriasis
- Pharmaceutical company
- Medac UK
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 October 2009